Cyclerion Therapeutics, Inc.
CYCN
$26.20
$2.6811.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.90M | 1.99M | 2.07M | 2.86M | 2.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.90M | 1.99M | 2.07M | 2.86M | 2.17M |
| Cost of Revenue | 1.60M | 1.65M | 959.00K | 496.00K | 229.00K |
| Gross Profit | 303.00K | 340.00K | 1.12M | 2.36M | 1.95M |
| SG&A Expenses | 7.13M | 7.07M | 6.09M | 5.99M | 5.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.72M | 8.72M | 7.05M | 6.49M | 5.93M |
| Operating Income | -6.82M | -6.73M | -4.97M | -3.63M | -3.76M |
| Income Before Tax | -6.71M | -5.28M | -3.53M | -2.20M | -1.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.71 | -5.28 | -3.53 | -2.20 | -1.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.71M | -5.28M | -3.53M | -2.20M | -1.95M |
| EBIT | -6.82M | -6.73M | -4.97M | -3.63M | -3.76M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -11.76 | -9.61 | -8.24 | -5.31 | -5.20 |
| Normalized Basic EPS | -7.35 | -7.88 | -7.03 | -5.20 | -5.12 |
| EPS Diluted | -11.76 | -9.61 | -8.24 | -5.31 | -5.20 |
| Normalized Diluted EPS | -7.35 | -7.88 | -7.03 | -5.20 | -5.12 |
| Average Basic Shares Outstanding | 2.21M | 2.04M | 1.81M | 1.63M | 1.53M |
| Average Diluted Shares Outstanding | 2.21M | 2.04M | 1.81M | 1.63M | 1.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |